首页> 外文期刊>Journal of Thoracic Disease >CT-guided fine-needle aspiration biopsy of solitary pulmonary nodules under 15 mm in diameter: time for an afterthought?
【24h】

CT-guided fine-needle aspiration biopsy of solitary pulmonary nodules under 15 mm in diameter: time for an afterthought?

机译:CT引导下直径小于15 mm的孤立性肺结节的细针穿刺活检:是时候考虑了吗?

获取原文
           

摘要

Background: Many studies on fine-needle aspiration biopsy (FNAB) for undetermined pulmonary nodules reported that diagnostic accuracy tended to decline, whereas complication prevalence raised as the size of nodule decreased. Reconsideration on the effectiveness of FNAB would be appropriate considering the dramatic increase in the identification of small nodules with screening programs and new demands of target therapies. The aim of this study was to verify the efficacy of FNAB in pulmonary nodules smaller than 15 mm. Methods: A retrospective, cohort study was conducted on patients with undetermined solitary pulmonary nodules (SPNs) who underwent computer tomography (CT) guided FNAB at our Institution from January 2012 to December 2014. Patients with SPNs with diameter up to 15 mm were considered; inclusion criteria comprised ASA 3, FEV1 Results: Out of 225 patients referred for FNAB, 68 covered inclusion criteria. The cohort’s prevalence of malignant pathology was 61%. Forty-nine out of 68 smears (72%) were adequate for diagnosis. Specificity was 100% (95% CI: 75–100%), sensitivity was 97.2% (95% CI: 86–100%). Positive and negative predictive values were 83% and 100%. A post-biopsy pneumothorax was detected in 27 cases (39%); the pneumothorax rate was significantly affected by the number of passages (P=0.01). Sixteen patients (23%) avoided unnecessary surgery. Conclusions: The satisfactory results of our study lead to reconsidering FNAB in patients with pulmonary nodules below 15 mm in diameter, especially in order to avoid unnecessary surgery.
机译:背景:关于未确定的肺结节的细针穿刺活检(FNAB)的许多研究报告,诊断准确性趋于下降,而并发症的发生率随着结节大小的减少而升高。考虑到通过筛查程序和目标疗法的新需求,对小结节的识别急剧增加,因此重新考虑FNAB的有效性是适当的。这项研究的目的是验证FNAB在小于15 mm的肺结节中的疗效。方法:回顾性队列研究对2012年1月至2014年12月在我们机构接受计算机断层扫描(CT)指导的FNAB的未确定的孤立性肺结节(SPN)的患者进行。研究对象考虑了直径最大为15 mm的SPN。纳入标准包括ASA 3,FEV1结果:在225名接受FNAB诊治的患者中,有68名纳入标准。该队列的恶性病理患病率为61%。 68个涂片中有49个涂片(72%)足以诊断。特异性为100%(95%CI:75-100%),敏感性为97.2%(95%CI:86-100%)。阳性和阴性预测值分别为83%和100%。活检后发现气胸27例(39%);气胸发生率显着受传次数的影响(P = 0.01)。 16名患者(23%)避免了不必要的手术。结论:我们的研究令人满意的结果导致对直径小于15 mm的肺结节患者重新考虑FNAB,特别是为了避免不必要的手术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号